Leading international experts are organizing a new high-level two-day meeting about the interdisciplinary challenges faced in pediatric drug development. The plan is for the meeting to become an annual event. Called ?Development of Medicines for Paediatric and Rare Diseases,? the conference will take place in Basel, Switzerland, on?February 3-4, 2015
Leading international experts are organizing a new high-level two-day meeting about the interdisciplinary challenges faced in pediatric drug development. The plan is for the meeting to become an annual event.
Called “Development of Medicines for Paediatric and Rare Diseases,” the conference will take place in Basel, Switzerland, on February 3-4, 2015. Longstanding enthusiasts Prof. Johannes van den Anker, MD, PhD, Professor of Paediatric Pharmacology and Chair, Department of Paediatric Pharmacology at the university hospital af Basel, Switzerland, and Klaus Rose, M.D., managing director of klausrose Consulting in Basel, are the heads of the organizing committee.
Among the program highlights will a presentation about the regulatory view on pediatric legislation, including its achievements and limitations, to be given by Dirk Menzer, chairman, EMA Paediatric Committee (PDCO).
“Awareness of the value of new medicines for children and adults has increased over the past decades, partially as a result of US and EU legislation on pediatric and orphan diseases. However, pediatric clinical practice has changed less than had been hoped for, and an initial enthusiasm has been replaced by a more realistic assessment,” stated the organizers.
European Union and U.S. orphan and pediatric legislation is intended to promote research in children, but the PDCO will block new drugs without an approved pediatric investigation plan (PIP), and the procedure can take about a year. The legislation has created pressure to develop child-adapted formulations, pediatric dosing recommendations, age-adapted preclinical safety and pediatric clinical safety and efficacy data for new drugs that are predominantly developed for adults, they continued.
“After 8 years in force, first assessments range from asking for tougher pressure on industry to questioning if worldwide drug development for children can be successfully improved by giving almost unlimited power to an EU committee,” they added.
The conference will provide an update on both state-of-the-art methodology and operational challenges in research and development. All the key players will be represented, and the interactive format will allow a hands-on exchange of ideas and experiences. The event aimsto re-evaluate what is needed for more progress in the development of treatments for both pediatric and rare diseases.
For organizational questions, contact [email protected]. For content questions, contact Johannes van den Anker ([email protected]) and Klaus Rose ([email protected]). For sponsorship information, contact Martin Austin ([email protected]).
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.